Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs

被引：0
|
作者：
Kojiro Maeda
Masayuki Kaneko
Mamoru Narukawa
Teruyo Arato
机构：
[1] Hokkaido University Graduate School of Medicine,Department of Regulatory Science
[2] Kitasato University,Department of Clinical Medicine (Pharmaceutical Medicine), Graduate School of Pharmaceutical Science
[3] Hokkaido University Hospital Clinic Research and Medical Innovation Center,undefined
来源：
Orphanet Journal of Rare Diseases | / 12卷
关键词：
Ultra-orphan drugs; Review reports; Clinical trials; Guidance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs
    Maeda, Kojiro
    Kaneko, Masayuki
    Narukawa, Mamoru
    Arato, Teruyo
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2017, 12
  • [2] The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review
    Schuller, Y.
    Hollak, C. E. M.
    Biegstraaten, M.
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2015, 10
  • [3] The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review
    Y. Schuller
    C. E. M. Hollak
    M. Biegstraaten
    [J]. Orphanet Journal of Rare Diseases, 10
  • [4] ORPHAN VERSUS ULTRA-ORPHAN DRUGS PRICES IN ENGLAND
    Achour, L.
    Hanna, E.
    Borrisov, B.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S446 - S446
  • [5] TITLE: ACCESS TO ORPHAN AND ULTRA-ORPHAN DRUGS IN CHINA
    Gambari, J.
    Yang, M.
    Chowdhury, C. A.
    Duttagupta, S.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A826 - A826
  • [6] ORPHAN DRUGS VERSUS ULTRA-ORPHAN DRUGS: PRICE COMPARISON IN ENGLAND
    Chachoua, L.
    Hanna, E.
    Zhou, J.
    Dussart, C.
    Toumi, M.
    [J]. VALUE IN HEALTH, 2018, 21 : S107 - S107
  • [7] Ultra-orphan drugs: can we afford the price
    Menon, Devidas
    Stafinski, Tania
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (08): : 611 - 612
  • [8] MARKET ACCESS AND PRICING ANALYSIS OF ULTRA-ORPHAN DRUGS
    Malacan, J.
    Gabriel, S.
    Dinet, J.
    Forget, S.
    Borget, I
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A257 - A257
  • [9] International differences in patient access to ultra-orphan drugs
    Kanters, Tim A.
    Redekop, W. Ken
    Hakkaart, Leona
    [J]. HEALTH POLICY AND TECHNOLOGY, 2018, 7 (01) : 57 - 64
  • [10] HOW DOES THE SCOTTISH MEDICINES CONSORTIUM ASSESS THE VALUE OF ORPHAN AND ULTRA-ORPHAN DRUGS?
    Rothwell, B.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A568 - A568
12345